Dexamethasone (dex) is a glucocorticoid that is a mainstay for treatment of inflammatory pathologies, including immunotherapy-associated toxicities. Dex suppresses the endogenous immune response and is also believed to suppress the function of chimeric antigen receptor (CAR) T cells. However, recent reports observed higher CAR T cell numbers in patients treated with dex, highlighting the rationale for interrogating the specific effects of dex on CAR T cells. Here, we found that dex did not inhibit CAR T cell expansion or function. A single dose of dex during the manufacturing process upregulated the pro-persistence interleukin 7 receptor α (IL7Rα) on CAR T cells and induced expression of genes involved in activation, migration, and persistence. The ex vivo upregulation of IL7Rα induced by dex significantly enhanced CAR T cell persistence and anti-tumor efficacy in vivo when combined with exogenous IL-7. Moreover, the combination of dex and IL-7 resulted in increased persistence of CAR T cells and led to complete remission of mice. Overall, our studies in both in vitro and in vivo treatment support a positive role of dex on CAR T cell potency and provide insight into the application of glucocorticoids in cellular anti-cancer therapy.
Background/Objectives: Paragangliomas (PGLs) and pheochromocytomas (PCCs) are rare neuroendocrine tumors. While external beam radiation therapy (EBRT), particularly stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), is established for head and neck PGLs (HNPGLs), its efficacy for non-head and neck PGLs (non-HNPGLs) and PCCs is less defined. We aimed to compare treatment outcomes of EBRT across these anatomic sites. Methods: We retrospectively reviewed patients with confirmed PGL or PCC treated with EBRT at a single institution between 1998 and 2025. Treated lesions were classified as non-HNPGL or HNPGL based on the radiation treatment field. Outcomes included local control (LC), distant progression-free survival (dPFS), overall survival (OS), symptomatic/biochemical response, and toxicity. We also conducted a systematic review examining EBRT for non-HNPGLs and PCCs following PRISMA guidelines. Results: We included 74 patients with 129 lesions who were treated with EBRT, with 62 HNPGL lesions and 67 non-HNPGL lesions. Of the non-HNPGL lesions, 50.7% (34/67) received SRS/SBRT with a median BED10 of 50.8 Gy (range, 35.7–112.5). 5-year LC rate for non-HNPGL lesions was 95.3%, compared to 100% for HNPGL lesions, with 78% of lesions achieving symptomatic control. For non-HNPGL patients, median dPFS and OS were 37.6 and 131 months, respectively. There were no acute or late G ≥ 3 toxicities. Our systematic review (61 studies, 183 patients) showed LC and symptomatic improvement ranges of 76–100% and 76–94%, respectively. Conclusions: EBRT, including SRS and SBRT, provides excellent local control and symptomatic relief for both non-HNPGLs and HNPGLs. It represents a safe, effective treatment option for these rare tumors regardless of anatomic location.